Loading clinical trials...
Loading clinical trials...
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a sequential group, single ascending (oral) dose stu...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
MyoKardia, Inc.
NCT07367724 · Obstructive Hypertrophic Cardiomyopathy (oHCM)
NCT05836259 · Hypertrophic Cardiomyopathy
NCT07054073 · Hypertrophic Cardiomyopathy (HCM)
NCT07344480 · Hypertrophic Cardiomyopathy (HCM), Heart Failure, and more
NCT06433050 · Hypertrophic Cardiomyopathy Without Obstruction
Scottsdale, Arizona
Cypress, California
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions